Avalo Therapeutics Inc
AVTX
NASDAQ
Biotechnology
$19.59
USD
+0.14 (+0.72%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $1.04B
Volume 387.5K
Revenue
$59,000
TTM
-86.6%
YoY
Gross Margin
100%
TTM
-58.7%
YoY
Net Income
$-100.33M
TTM
-117.1%
YoY
Operating Cash Flow
$-68.29M
TTM
-44.0%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 |
YoY Growth | — | -100.0% | -69.3% | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 |
Selling, General & Administrative | 5.2 | 5.6 | 6.5 | 6.9 | 8.1 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 19.3 | 19.2 | 19.8 | 20.9 | 31.5 |
Operating Income | -19.3 | -19.2 | -19.7 | -20.9 | -31.5 |
EBITDA | -19.2 | -19.1 | -19.7 | -20.9 | -31.5 |
Other Income / Expense | -2.5 | -12.5 | 5.2 | 0.5 | -7.6 |
Total Other Income / Expense | -1.4 | -11.4 | 6.2 | 1.3 | -4.8 |
Income Before Income Taxes | -20.7 | -30.6 | -13.6 | -19.6 | -36.3 |
Income Taxes | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 |
Net Income | -20.8 | -30.6 | -13.7 | -19.6 | -36.4 |
Consolidated Net Income / Loss | -20.8 | -30.6 | -13.7 | -19.6 | -36.4 |
Net Income Attributable to Common Shareholders | -20.8 | -30.6 | -13.7 | -19.6 | -36.4 |
Basic EPS | -$1.92 | -$2.19 | -$0.75 | -$0.98 | -$0.83 |
Diluted EPS | -$1.92 | -$2.19 | -$0.75 | -$0.98 | -$0.83 |
Basic Shares Outstanding | 10.8M | 14.0M | 18.3M | 20.1M | 43.6M |
Diluted Shares Outstanding | 10.8M | 14.0M | 18.3M | 20.1M | 43.6M |